

PGT-M Update - Igenomix clinical results

PGT-M prevents the transmission of single gene conditions to offspring. This test is for individuals and couples with known carrier status for monogenic conditions such as cystic fibrosis, fragile X syndrome or Huntington disease, among others.

IGENOMIX NORTH AMERICA

Patients

5,365

Genes analyzed


745

Embryos analyzed with PGT-M

24,234



>99%



PGT-M can be performed for >99% of inherited single gene conditions




>65%



Igenomix has previously tested >65% of variants for which **PGT-M** is requested

PGT-A and PGT-M can be performed on the same sample



The vast majority (95%) of patients and providers request PGT-A in addition to PGT-M


>98%

PGT-M identifies affected and unaffected embryos with >98% accuracy

>76% of cases

Direct variant detection, in addition to linkage analysis, is performed in over 76% of cases.

Direct detection allows PGT-M to be available for patients who do not have relatives available to provide DNA samples for probe development.




<5%



NON-INFORMATIVE EMBRYOS



<1%



NON-ACCEPTED CASES (Due to technical complexity)